ArticleCancer gene therapy2026
VPS37A loss creates CASP8-dependent vulnerability via the MAP3K7-NF-κB-CFLAR axis.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
VPS37A, a subunit of ESCRT-I involved in endosomal sorting and autophagy, is frequently downregulated in diverse human cancers. In this study, we showed that VPS37A downregulation, as part of a large chromosome 8p deletion, arises early during tumorigenesis and persists throughout tumor progression. Integrative analysis of VPS37A gene copy number and CRISPR dependency revealed that VPS37A deficiency creates a synthetic lethal dependency on the MAP3K7-NF-κB-CFLAR axis, and targeting this axis triggered CASP8-mediated apoptosis and suppressed tumor growth. This synthetic vulnerability depends on ATG8ylated membranes, which serve as a platform for CASP8 activation upon inhibition of phagophore closure, and can be triggered without disrupting receptor sorting. Consistently, despite frequent co-deletion of VPS37A and the death receptors TNFRSF10A/B, inhibition of the MAP3K7-NF-κB-CFLAR axis selectively induced apoptosis in spheroid tumors with 8p deletion. These results uncover a selective vulnerability in cancer cells harboring VPS37A/8p loss, providing a mechanistic rationale for targeted therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.